Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars
PR90262
BEIJING, June 23, 2021 /PRNewswire=KYODO JBN/ --
Biocytogen (https://biocytogen.com/), an international biotechnology company
focused on antibody drug research and development (R&D) using innovative
genetically engineered animal models, today announced the successful completion
of a new round of financing totaling tens of millions of dollars. The financing
was jointly completed by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was established in 2009. Using
its foundational gene editing technology, the company independently developed
mouse platforms for fully human antibody discovery, RenMab(R) and RenLite(R)
(https://renmab.com/), that have independent intellectual property rights. With
the implementation of these platforms, Biocytogen has evolved from a contract
research organization (CRO) into an international biotechnology company with
expertise spanning the entire process of new drug R&D, including antibody drug
target verification, high-throughput single B cell antibody discovery
technology, in vivo drug efficacy evaluation using humanized target mice, and
clinical development.
Genetic engineering of RenMab(R)and RenLite(R) mice has enabled the integration
of Biocytogen's technological strengths into a unique large-scale R&D plan for
the discovery of therapeutic antibodies, an initiative termed the RenMice HiTS
Platform (https://renmab.com/about-hits-platform/). The HiTS Platform signifies
the company's commitment to complete high-efficiency antibody discovery and in
vivo drug efficacy screening of more than 1,000 antibody targets in the next
few years, focusing on the discovery of first-in-class and best-in-class drug
targets. Through the identification of antibody leads that have been verified
for efficacy in animal models, Biocytogen has established co-development
partnerships with more than a dozen biotechnology and pharmaceutical companies.
Dr. Yuelei Shen, founder and CEO of Biocytogen, said:
"In the two months from initiation to completion of this round of financing,
the company has received extensive attention and recognition from top
biomedical funds and long-term investment institutions. New shareholders with
outstanding reputations are very welcome to join the Biocytogen family.
Paying attention to the R&D and innovation of the underlying technology is the
cornerstone of our development. After more than ten years of large-scale R&D
investment, we have achieved good results in the fields of super-large fragment
gene editing technology, fully human antibody gene mouse development
technology, and bispecific antibody development technology. These breakthroughs
in the underlying technology have enabled the company to continue to explore in
the fields of monoclonal antibodies, bispecific antibodies, bispecific
antibody-ADCs, and nanobodies.
The antibody drug molecules YH003 ([anti-]CD40) and YH001 ([anti-]CTLA-4)
independently developed by Biocytogen and its wholly-owned subsidiary, Eucure
Biopharma, are in phase I clinical trials in Australia in combination with
Junshi Biosciences' PD-1 antibody Toripalimab. Both show excellent safety and
good drug efficacy. The in vivo experimental data of YH003 and YH001 have been
well verified in the preclinical stage, fully demonstrating the high
reliability of the biopharmaceutical research and development method that uses
animal efficacy data as the "gold standard" for drug preclinical screening."
For more about this fundraising initiative, click here (
).
Source: Biocytogen
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。